The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy. To treat the disease successfully, new therapeutic strategies are urgently needed. One of these strategies can be the use of neurokinin-1 receptor (NK-1R) antagonists (e.g., aprepitant), because the substance P (SP)/NK-1R syst...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Miguel Muñoz, Rafael Coveñas
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI AG 2020-06-01
Serie:Journal of Clinical Medicine
Soggetti:
substance P
NK-1R
AML
aprepitant
anti-leukemic
apoptosis
Accesso online:https://www.mdpi.com/2077-0383/9/6/1659
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi